Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.

Journal of neuro-oncology - 1 Oct 2022

Weller Jonathan, Katzendobler Sophie, Blobner Jens, Thiele Frederic, Becker Hannes, Quach Stefanie, Egensperger Rupert, Niyazi Maximilian, Suchorska Bogdana, Thon Niklas, Weller Michael, Tonn Joerg-Christian

Abstract excerpt

PURPOSE: The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined. Radiotherapy might be superior to temozolomide. Recent studies have linked temozolomide with induction of hypermutation and poor clinical course in some IDH-mutant gliomas. METHODS: In this retrospective study, 183 patients with astrocytoma, IDH-mutant, CNS WHO grade 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Temozolomide
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytoma

Share to Brain Neoplasms

Share to Dacarbazine

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 36112301
DOI: 10.1007/s11060-022-04128-y
PMCID: PMC9622511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.PMID 36112301Read ↗

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Early progressive disease in IDH-mutant grade 2 and 3 astrocytoma without CDKN2A/B homozygous deletions may indicate radiation necrosisSemantic proximity Read ↗

Current Considerations in the Treatment of Grade 3 Gliomas.Semantic proximity Read ↗

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.Semantic proximity Read ↗

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.Semantic proximity Read ↗

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.Semantic proximity Read ↗

A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.Semantic proximity Read ↗

Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.Semantic proximity Read ↗

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.Semantic proximity Read ↗

Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.